Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after anti-TNF failure.

Like Comment
Dear Editor, hidradenitis suppurativa (HS) is a relapsing inflammatory skin disease. The cytokines IL-1β, IL-12, IL-23, IL-17 and TNF-α are involved in the inflammatory process. The only approved drug for the treatment of moderate-to-severe cases is adalimumab (TNF-α inhibitor). However, long-term clinical responses range only from 52-57%. Tildrakizumab (anti-IL-23), guselkumab (anti-IL-23) and ustekinumab (anti-IL-12/23) have been successfully used in HS.


View the full article @ The British journal of dermatology


Get PDF with LibKey

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6584 Contributions
2 Followers
0 Following